The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT® (valsartan and hydrochlorothiazide) and Exforge® (amlodipine and valsartan), as initial or ‘first-line’ therapies in patients likely to need multiple drugs to achieve their blood pressure goals.
The FDA approval of

New clinical data presented show first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in patients with high blood pressure aged 65 and over, compared to the angiotensin-converting enzyme (ACE) inhibitor ramipril[1].
Results from the

The US Food and Drug
Administration (FDA) has approved two single-pill combination medications,
Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge(R)
(amlodipine and valsartan), as initial or ‘first-line’ therapies in
patients likely to need multiple drugs to achieve their blood pressure